+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Pulmonary Drugs Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2025

  • ID: 4770300
  • Report
  • Region: Global
  • 100 pages
  • Infinium Global Research
UP TO OFF
until Dec 31st 2019
1 of 3

FEATURED COMPANIES

  • AstraZeneca
  • Bayer AG
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc.
  • Merck Sharp & Dohme Corp
  • Novartis AG
  • MORE
The report on the global pulmonary drugs market provides qualitative and quantitative analysis for the period from 2017 to 2025. The report predicts the global pulmonary drugs market to grow with a CAGR of 4.3% over the forecast period from 2019-2025. The study on pulmonary drugs market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2017 to 2025.

The report on pulmonary drugs market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global pulmonary drugs market over the period of 2017 to 2025. Moreover, the report is a collective presentation of primary and secondary research findings.

Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global pulmonary drugs market over the period of 2017 to 2025. Further, IGR- Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.

Report Findings
1) Drivers
  • Growing prevalence chronic obstructive pulmonary disease (COPD)
  • Potential advantages of the pulmonary route as an alternative to oral and parenteral delivery methods
  • Rising incidence of lung diseases
2) Restraints
  • Less awareness regarding pulmonary drugs delivery
3) Opportunities
  • Increasing government initiatives
Research Methodology
A) Primary Research

Our primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include
1. Key Opinion Leaders associated with the Publisher
2. Internal and External subject matter experts
3. Professionals and participants from the industry

Our primary research respondents typically include
1. Executives working with leading companies in the market under review
2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/ country managers
5. Vice President level executives.

B) Secondary Research

Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. Each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include
1. Company reports and publications
2. Government/institutional publications
3. Trade and associations journals
4. Databases such as WTO, OECD, World Bank, and among others.
5. Websites and publications by research agencies

Segment Covered
The global pulmonary drugs market is segmented on the basis of drug class, application, and distribution channel.

The Global Pulmonary Drugs Market by Drug Class
  • Long-acting Beta2-agonists (LABA)
  • Short-acting Beta2-agonists (SABA)
  • Anticholinergics
  • Inhaled Corticosteroids (ICS)
  • Antihistamines
  • Vasodilators
  • Other drug class
The Global Pulmonary Drugs Market by Application
  • Pulmonary Arterial Hypertension
  • Cystic Fibrosis
  • Asthma & COPD
  • Other applications
The Global Pulmonary Drugs Market by Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Other Distribution Channels
Company Profiles
The companies covered in the report include
  • Sunovion Pharmaceuticals Inc.
  • AstraZeneca
  • Novartis AG
  • Bayer AG
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc.
  • Teva Pharmaceutical Industries Ltd.
  • Merck Sharp & Dohme Corp
  • Boehringer Ingelheim International GmbH.
  • Actelion Pharmaceuticals Ltd
  • Others
What does this report deliver?
1. Comprehensive analysis of the global as well as regional markets of the pulmonary drugs market.
2. Complete coverage of all the segments in the pulmonary drugs market to analyze the trends, developments in the global market and forecast of market size up to 2025.
3. Comprehensive analysis of the companies operating in the global pulmonary drugs market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and the latest developments of the company.
4. IGR- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AstraZeneca
  • Bayer AG
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc.
  • Merck Sharp & Dohme Corp
  • Novartis AG
  • MORE
1. Preface
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches

2. Executive Summary
2.1. Pulmonary Drugs Market Highlights
2.2. Pulmonary Drugs Market Projection
2.3. Pulmonary Drugs Market Regional Highlights

3. Global Pulmonary Drugs Market Overview
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. Porter's Five Forces Analysis
3.4. IGR-Growth Matrix Analysis
3.4.1. IGR-Growth Matrix Analysis by Drug Class
3.4.2. IGR-Growth Matrix Analysis by Application
3.4.3. IGR-Growth Matrix Analysis by Distribution Channel
3.4.4. IGR-Growth Matrix Analysis by Region
3.5. Value Chain Analysis of Pulmonary Drugs Market

4. Pulmonary Drugs Market Macro Indicator Analysis

5. Global Pulmonary Drugs Market by Drug Class
5.1. Long-acting Beta2-agonists (LABA)
5.2. Short-acting Beta2-agonists (SABA)
5.3. Anticholinergics
5.4. Inhaled Corticosteroids (ICS)
5.5. Antihistamines
5.6. Vasodilators
5.7. Other drug class

6. Global Pulmonary Drugs Market by Application
6.1. Pulmonary Arterial Hypertension
6.2. Cystic Fibrosis
6.3. Asthma & COPD
6.4. Other applications

7. Global Pulmonary Drugs Market by Distribution Channel
7.1. Hospital Pharmacies
7.2. Retail Pharmacies
7.3. Drug Stores
7.4. Other distribution channel

8. Global Pulmonary Drugs Market by Region 2019-2025
8.1. North America
8.1.1. North America Pulmonary Drugs Market by Drug Class
8.1.2. North America Pulmonary Drugs Market by Application
8.1.3. North America Pulmonary Drugs Market by Distribution Channel
8.1.4. North America Pulmonary Drugs Market by Country
8.2. Europe
8.2.1. Europe Pulmonary Drugs Market by Drug Class
8.2.2. Europe Pulmonary Drugs Market by Application
8.2.3. Europe Pulmonary Drugs Market by Distribution Channel
8.2.4. Europe Pulmonary Drugs Market by Country
8.3. Asia-Pacific
8.3.1. Asia-Pacific Pulmonary Drugs Market by Drug Class
8.3.2. Asia-Pacific Pulmonary Drugs Market by Application
8.3.3. Asia-Pacific Pulmonary Drugs Market by Distribution Channel
8.3.4. Asia-Pacific Pulmonary Drugs Market by Country
8.4. RoW
8.4.1. RoW Pulmonary Drugs Market by Drug Class
8.4.2. RoW Pulmonary Drugs Market by Application
8.4.3. RoW Pulmonary Drugs Market by Distribution Channel
8.4.4. RoW Pulmonary Drugs Market by Sub-region

9. Company Profiles and Competitive Landscape
9.1. Competitive Landscape in the Global Pulmonary Drugs Market
9.2. Companies Profiles
9.2.1. Sunovion Pharmaceuticals Inc.
9.2.2. AstraZeneca
9.2.3. Novartis AG
9.2.4. Bayer AG
9.2.5. F. Hoffmann-La Roche Ltd
9.2.6. GlaxoSmithKline plc.
9.2.7. Teva Pharmaceutical Industries Ltd.
9.2.8. Merck Sharp & Dohme Corp
9.2.9. Boehringer Ingelheim International GmbH.
9.2.10. Actelion Pharmaceuticals Ltd
9.2.11. Others

10. Appendix
10.1. Primary Research Findings and Questionnaire
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Sunovion Pharmaceuticals Inc.
  • AstraZeneca
  • Novartis AG
  • Bayer AG
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc.
  • Teva Pharmaceutical Industries Ltd.
  • Merck Sharp & Dohme Corp
  • Boehringer Ingelheim International GmbH.
  • Actelion Pharmaceuticals Ltd
Note: Product cover images may vary from those shown
Adroll
adroll